Coronary flow improvement following unsuccessful primary percutaneous coronary intervention in ST-elevation

Toshiharu Fujii1, Katsuaki Sakai1, Manabu Kimura1

  • 1Division of Cardiology, Tokai University School of Medicine, Isehara, Japan.

Insights

Patients with ST-elevation myocardial infarction and diffuse ectatic coronary arteries had lower initial blood flow success rates after percutaneous coronary intervention. However, coronary flow improved significantly by follow-up, with lower mortality rates observed in this group.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Biology

Background:

  • ST-elevation myocardial infarction (STEMI) with diffuse ectatic coronary arteries presents challenges for successful revascularization.
  • Extensive thrombi in these conditions often hinder achieving optimal Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow post-primary percutaneous coronary intervention (PCI).
  • Clinical and angiographic outcomes for STEMI patients with giant coronary artery ectasia remain uncertain.

Purpose of the Study:

  • To investigate the clinical and angiographic outcomes of STEMI patients with giant coronary artery ectasia.
  • To compare PCI success rates and long-term outcomes between patients with and without coronary artery ectasia.

Main Methods:

  • Retrospective analysis of 744 STEMI patients undergoing primary PCI.
  • Comparison of the Ectatic group (n=39) with the Non-ectatic group (n=705).
  • Assessment of PCI success rate, angiographic outcomes, and clinical outcomes at 360 days.

Main Results:

  • PCI success rate, defined by final TIMI grade 3 flow, was significantly lower in the Ectatic group (53.8%) compared to the Non-ectatic group (92.9% and 93.5%, p<0.0001).
  • Significant angiographic improvement to TIMI grade 3 flow was observed by follow-up in 86% of the Ectatic group, versus only 25% in the Non-ectatic group.
  • All-cause 360-day mortality was significantly lower in the Ectatic group (2.6%) than in the Non-ectatic group (14.5%, p=0.0361).

Conclusions:

  • STEMI patients with giant coronary artery ectasia experience reduced immediate TIMI grade 3 flow achievement post-PCI.
  • Coronary flow improvement to TIMI grade 3 is common at follow-up angiography in this patient cohort.
  • Despite lower initial procedural success, patients with diffuse ectatic coronary arteries in STEMI exhibit favorable long-term mortality outcomes.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.5K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
439
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
695
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
545